Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The screenshots show only minor formatting and timestamp updates, with no changes to eligibility criteria, study design, endpoints, or recruitment locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-10-27T20:53:23.000Z thumbnail image
  3. Check
    32 days ago
    Change Detected
    Summary
    Core content updated to inform users about funding-related operating status and current NIH Clinical Center openness; version updated from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-06T08:10:21.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Page now shows Revision: v3.1.0 and adds a batch of contact details (phone numbers and emails) for various individuals. Deletion indicates removal of v3.0.2.
    Difference
    0.1%
    Check dated 2025-09-29T04:44:02.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.
    Difference
    0.2%
    Check dated 2025-09-14T22:23:30.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T19:33:25.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new related topics such as Salivary Gland Cancer and various hormones. Notably, previous content related to Oral Cancer and several specific neoplasms has been removed.
    Difference
    4%
    Check dated 2025-08-31T12:37:24.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.